An Open-Label, Randomized, Phase 1, Single-Dose Crossover, Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Trial Profile

An Open-Label, Randomized, Phase 1, Single-Dose Crossover, Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Pegvisomant (Primary)
  • Indications Acromegaly
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Dec 2013 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 06 Nov 2013 Planned End Date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 23 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top